As Pacira Pharmaceuticals (PCRX) Stock Rose, Clough Capital Partners LP Boosted Position; As Host Hotels & Resorts (HST) Stock Declined, Shareholder Green Street Investors Has Lifted Its Position

January 14, 2018 - By Vivian Park

Green Street Investors Llc increased its stake in Host Hotels & Resorts Inc (HST) by 14.48% based on its latest 2017Q3 regulatory filing with the SEC. Green Street Investors Llc bought 56,700 shares as the company’s stock declined 1.63% while stock markets rallied. The institutional investor held 448,400 shares of the consumer services company at the end of 2017Q3, valued at $8.29M, up from 391,700 at the end of the previous reported quarter. Green Street Investors Llc who had been investing in Host Hotels & Resorts Inc for a number of months, seems to be bullish on the $15.24B market cap company. The stock decreased 1.02% or $0.21 during the last trading session, reaching $20.36. About 5.17M shares traded. Host Hotels & Resorts, Inc. (NYSE:HST) has risen 23.72% since January 14, 2017 and is uptrending. It has outperformed by 7.02% the S&P500.

Charles Clough increased its stake in Pacira Pharmaceuticals Inc (PCRX) by 842.56% based on its latest 2017Q3 regulatory filing with the SEC. Clough Capital Partners LP bought 164,300 shares as the company’s stock rose 10.53% with the market. The hedge fund run by Charles Clough held 183,800 shares of the health care company at the end of 2017Q3, valued at $6.90 million, up from 19,500 at the end of the previous reported quarter. Clough Capital Partners LP who had been investing in Pacira Pharmaceuticals Inc for a number of months, seems to be bullish on the $1.68 billion market cap company. The stock decreased 1.72% or $0.72 during the last trading session, reaching $41.5. About 1.03M shares traded or 26.65% up from the average. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has risen 12.40% since January 14, 2017 and is uptrending. It has underperformed by 4.30% the S&P500.

Investors sentiment decreased to 1.14 in 2017 Q3. Its down 0.12, from 1.26 in 2017Q2. It fall, as 39 investors sold HST shares while 143 reduced holdings. 47 funds opened positions while 161 raised stakes. 739.84 million shares or 2.86% less from 761.66 million shares in 2017Q2 were reported. Moreover, Tiaa Cref Invest Mgmt Ltd has 0.04% invested in Host Hotels & Resorts, Inc. (NYSE:HST) for 3.19 million shares. American & Mngmt Co stated it has 0% of its portfolio in Host Hotels & Resorts, Inc. (NYSE:HST). Johnson Inv Counsel holds 0.01% of its portfolio in Host Hotels & Resorts, Inc. (NYSE:HST) for 10,726 shares. Group One Trading LP invested 0% of its portfolio in Host Hotels & Resorts, Inc. (NYSE:HST). Cibc Asset Inc holds 0.01% of its portfolio in Host Hotels & Resorts, Inc. (NYSE:HST) for 72,026 shares. Amer Interest Gru accumulated 0.02% or 320,646 shares. Assets Invest Mngmt Lc has 0.17% invested in Host Hotels & Resorts, Inc. (NYSE:HST) for 45,000 shares. 12.16 million are held by Pggm. Apg Asset Management Us reported 2.09% stake. Cadence Capital Limited Liability Corp accumulated 53,786 shares. 25,000 were reported by Wexford Capital L P. Btim Corporation accumulated 100,075 shares or 0.03% of the stock. Mai Capital Mgmt reported 0.01% of its portfolio in Host Hotels & Resorts, Inc. (NYSE:HST). Rothschild Invest Corp Il reported 0.12% in Host Hotels & Resorts, Inc. (NYSE:HST). Schroder Mngmt has invested 0.01% in Host Hotels & Resorts, Inc. (NYSE:HST).

Among 23 analysts covering Host Hotels & Resorts (NYSE:HST), 10 have Buy rating, 1 Sell and 12 Hold. Therefore 43% are positive. Host Hotels & Resorts had 67 analyst reports since July 31, 2015 according to SRatingsIntel. Argus Research downgraded the stock to “Hold” rating in Thursday, December 15 report. The rating was maintained by Argus Research on Wednesday, August 24 with “Buy”. Argus Research maintained the shares of HST in report on Wednesday, September 30 with “Buy” rating. M Partners maintained the stock with “Sell” rating in Tuesday, August 11 report. The stock of Host Hotels & Resorts, Inc. (NYSE:HST) has “Hold” rating given on Friday, July 28 by Boenning & Scattergood. The rating was upgraded by Raymond James on Monday, January 8 to “Outperform”. On Friday, July 31 the stock rating was maintained by Deutsche Bank with “Hold”. The rating was downgraded by Cowen & Co on Wednesday, September 16 to “Market Perform”. RBC Capital Markets maintained Host Hotels & Resorts, Inc. (NYSE:HST) rating on Wednesday, July 26. RBC Capital Markets has “Hold” rating and $2000 target. The stock of Host Hotels & Resorts, Inc. (NYSE:HST) has “Hold” rating given on Wednesday, August 12 by Deutsche Bank.

Since December 18, 2017, it had 0 insider purchases, and 1 insider sale for $1.23 million activity.

Among 21 analysts covering Pacira Pharmaceuticals (NASDAQ:PCRX), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Pacira Pharmaceuticals had 80 analyst reports since July 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, October 4 by Bank of America. The rating was initiated by Goldman Sachs with “Neutral” on Thursday, December 1. H.C. Wainwright maintained it with “Buy” rating and $5900 target in Thursday, August 3 report. As per Monday, August 21, the company rating was upgraded by Janney Capital. The stock has “Hold” rating by Oppenheimer on Wednesday, September 6. The firm has “Outperform” rating by Wedbush given on Thursday, August 20. The rating was maintained by H.C. Wainwright on Tuesday, July 25 with “Buy”. Wedbush maintained Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) rating on Wednesday, March 22. Wedbush has “Outperform” rating and $89 target. The stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) has “Buy” rating given on Wednesday, August 2 by Piper Jaffray. The firm has “Buy” rating given on Wednesday, June 21 by Wedbush.

Investors sentiment decreased to 1.39 in Q3 2017. Its down 0.23, from 1.62 in 2017Q2. It worsened, as 35 investors sold PCRX shares while 37 reduced holdings. 29 funds opened positions while 71 raised stakes. 41.63 million shares or 5.80% more from 39.35 million shares in 2017Q2 were reported. Pacad Inv Ltd has invested 0.02% in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). Blackrock Incorporated reported 3.32M shares or 0.01% of all its holdings. 25,539 were reported by Sei Invs Company. Invesco Limited has 666,176 shares. Moreover, Rhumbline Advisers has 0% invested in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 50,179 shares. Westfield Capital Mgmt Communication Ltd Partnership holds 0.37% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) for 1.29 million shares. California Employees Retirement owns 65,900 shares. Td Asset Management accumulated 25,800 shares. Barclays Public Limited Liability reported 0% stake. Baillie Gifford And, United Kingdom-based fund reported 320,582 shares. Alliancebernstein LP holds 58,230 shares. Mutual Of America Capital Ltd, New York-based fund reported 151,078 shares. Alps has invested 0.01% of its portfolio in Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX). 1.79M were reported by Price T Rowe Assoc Md. Consonance Capital Management LP owns 1.38M shares.

Since August 15, 2017, it had 0 insider purchases, and 4 insider sales for $1.23 million activity. Another trade for 1,044 shares valued at $37,741 was made by HASTINGS PAUL J on Tuesday, August 22. $1.05 million worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by STACK DAVID M on Tuesday, August 15. $14,858 worth of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was sold by Riker Lauren Bullaro on Friday, December 15.

Clough Capital Partners L P, which manages about $5.01 billion and $1.49 billion US Long portfolio, decreased its stake in Cognizant Technology Solutio (NASDAQ:CTSH) by 9,800 shares to 328,900 shares, valued at $23.86 million in 2017Q3, according to the filing. It also reduced its holding in Service Corp Intl (NYSE:SCI) by 31,200 shares in the quarter, leaving it with 199,668 shares, and cut its stake in Advent Claymore Enh Grw & In (LCM).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Twitter Auto Publish Powered By : XYZScripts.com